Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)‘s stock had its “buy” rating reiterated by equities researchers at Canaccord Genuity in a research note issued to investors on Saturday. They presently have a $10.00 price objective on the stock. Canaccord Genuity’s price objective would indicate a potential upside of 112.77% from the stock’s current price.

Several other equities analysts have also weighed in on AUPH. HC Wainwright began coverage on Aurinia Pharmaceuticals in a report on Thursday, June 30th. They set a “buy” rating and a $7.00 price objective for the company. Leerink Swann reaffirmed an “outperform” rating and issued a $7.00 price target on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 6th. Finally, FBR & Co reaffirmed an “outperform” rating and issued a $9.00 price target on shares of Aurinia Pharmaceuticals in a report on Tuesday. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. Aurinia Pharmaceuticals presently has an average rating of “Buy” and an average target price of $7.75.

Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 4.70 on Friday. The company’s 50-day moving average price is $2.45 and its 200-day moving average price is $2.78. The company’s market cap is $165.84 million. Aurinia Pharmaceuticals has a 12 month low of $1.42 and a 12 month high of $5.69.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

An institutional investor recently raised its position in Aurinia Pharmaceuticals stock. Lombard Odier Asset Management USA Corp raised its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) by 2.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 102,294 shares of the company’s stock after buying an additional 2,813 shares during the period. Lombard Odier Asset Management USA Corp owned 0.29% of Aurinia Pharmaceuticals worth $283,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 20.04% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

5 Day Chart for NASDAQ:AUPH

Receive News & Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.